PLRX.US Pliant Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.6932 USD
Close of Nov 17, 2026
0.6600 1.67
Market cap
USD 43.0M
P/E
-
P/B
0.34x
ROE
-70.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PLRX.US undervalued?

Graham number

The Graham number of Pliant Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pliant Therapeutics Inc fundamental analysis

No fundamental analysis for Pliant Therapeutics Inc yet.

Pliant Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusin…

Full company profile